Annual report pursuant to Section 13 and 15(d)

BUSINESS COMBINATIONS AND ASSET PURCHASES - Summary of Preliminary Allocation of Purchase Consideration (Details)

v3.22.4
BUSINESS COMBINATIONS AND ASSET PURCHASES - Summary of Preliminary Allocation of Purchase Consideration (Details) - USD ($)
$ in Thousands
 1 Months Ended
Dec. 31, 2022
Apr. 30, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash consideration:        
Less cash acquired $ (2,300)      
Fair value of assets acquired and (liabilities assumed):        
Goodwill $ 8,079   $ 2,068 $ 2,068
Kind Therapeutics USA Inc.        
Cash consideration:        
Cash paid at closing   $ 10,128    
Release of escrow   2,444    
Severance paid from escrow   556    
Less cash acquired   (2,310)    
Net cash consideration   10,818    
Note payable   5,634    
Write-off of accounts receivable   658    
Write-off of deferred accounts receivable   842    
Total fair value of consideration transferred   17,952 $ 13,100  
Fair value of assets acquired and (liabilities assumed):        
Current assets, net of cash acquired   5,047    
Property and equipment   622    
Goodwill   6,011    
Current liabilities   (511)    
Fair value of net assets acquired   17,952    
Kind Therapeutics USA Inc. | Trade name and trademarks        
Fair value of assets acquired and (liabilities assumed):        
Intangible assets:   2,041    
Kind Therapeutics USA Inc. | Non-compete agreements        
Fair value of assets acquired and (liabilities assumed):        
Intangible assets:   4,700    
Kind Therapeutics USA Inc. | Licenses and customer base        
Fair value of assets acquired and (liabilities assumed):        
Intangible assets:   $ 42